Unlike natalizumab (which targets ITGA4 and prevents the ability of α4β4 or α4β7 integrin to bind VCAM-1), a single treatment targeting ITGB1 would prevent tumor cells from adhering to a number of ECM ligands, including fibronectin, collagen IV, and laminin [150]. Here, ITGB1 is linked to neoplasm.